Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

Angiotensin II Receptor BlockersCandesartan4-32mg PO Q24HAdminister Anytime During HD; Post HD if Hypotensive

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
440529-137.3-12990.13N/A0 (high flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
  • Ottosson P, Attman P-O, Agren A-C, Samuelsson O. Candesartan cilexetil in haemodialysis patients. Clinical drug investigation. 2003;23(8):545-50.
  • Schulz E, Bahri S, Schettler V, Popov A-frederik, Hermann M. Pharmacokinetics and Antihypertensive Effects of Candesartan Cilexetil in Patients Undergoing Haemodialysis. Clinical drug investigation. 2009;29(11):713-719.